Summary
PRA recently performed a feasibility study to identify investigators who see patients with a rare neuromuscular autoimmune disease and who have the capability to perform a Phase II clinical trial. It was estimated that there may only be 1,000 to 3,000 patients in the US and Europe with the condition. By identifying 88 interested investigators and areas of high prevalence during the feasibility study, PRA and the sponsor developed a unique, data-based strategy for the clinical program.
Register to download
Feasibility Defines a Unique Enrollment Strategy
You may also be interested in:
Case Study
Complex Feasibility Assessment in Low- & Middle-Income Countries
Complex Feasibility Assessment in Low- & Middle-Income Countries.
White Paper
Clinical Trials in Children with Impaired Mental Capacity
Download this resource to learn how to conduct studies with patients who lack legal competence and the 4 ethical pillars of medical research.
Case Study
PRA Exceeds Tough Enrollment Goals
A Phase IIb, double-blind, randomized, parallel-group, placebo-controlled study to evaluate the safety, tolerability and efficacy of Study Drug in…